Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Retained Earnings (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Retained Earnings for 13 consecutive years, with $873000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 86.54% to $873000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $873000.0 through Dec 2025, up 86.54% year-over-year, with the annual reading at $873000.0 for FY2025, 86.54% up from the prior year.
  • Retained Earnings for Q4 2025 was $873000.0 at Madrigal Pharmaceuticals, up from -$2.0 billion in the prior quarter.
  • The five-year high for Retained Earnings was $1.3 million in Q3 2024, with the low at -$2.0 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$419.6 million, with a median of -$270000.0 recorded in 2024.
  • The sharpest move saw Retained Earnings tumbled 1419887.23% in 2021, then surged 3126.19% in 2024.
  • Over 5 years, Retained Earnings stood at -$667.3 million in 2021, then crashed by 44.27% to -$962.7 million in 2022, then soared by 100.05% to $468000.0 in 2023, then changed by 0.0% to $468000.0 in 2024, then skyrocketed by 86.54% to $873000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $873000.0, -$2.0 billion, and -$1.9 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.